Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | F13A1 | P00488 | 3/20 | 0.50 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22190396 | 0.94 | MAPK1 (0.55) | MAPTRXFP1F13A1FABP4HDAC3 | |
| SCHEMBL5846204 | 0.85 | FFAR1 (0.61) | FFAR1FFAR4RXRARXRBRXRG | |
| SCHEMBL27755047 | 0.84 | PARP10 (0.40) | MAPTRXFP1HDAC3HDAC4HDAC1 | |
| SCHEMBL3249491 | 0.82 | MAPT (0.62) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL8357921 | 0.81 | MAPT (0.52) | MAPTRXFP1F13A1FABP4HDAC3 | |
| SCHEMBL9663089 | 0.80 | MAPT (0.66) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL765851 | 0.80 | MAPT (0.66) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL713464 | 0.80 | MAPT (0.66) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL29057552 | 0.80 | MAPT (0.66) | MAPTRXFP1HDAC3MAPK1ADRA1A | |
| SCHEMBL1066202 | 0.80 | MAPT (0.66) | MAPTRXFP1HDAC3MAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171516-A1 | PEPTIDE ACIDS AS A GLP1R AGONIST AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2025096921-A1 | PEPTIDE ACIDS AS A GLP1R AGONIST AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-116615251-A | Antibody-drug conjugates comprising GLP1 peptide mimetics and the uses thereof | 瑞泽恩制药公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-106414434-A | Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes | 詹森药业有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-105209446-A | GPR120 agonists for the treatment of type ii diabetes | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | disclosed |
| CN-105209444-A | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV | 2015-12-30 | — | — | CN | disclosed |
| CN-105008345-A | BICYCLIC PYRROLE DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV | 2015-10-28 | — | — | CN | disclosed |
| CN-101068783-A | Processes and intermediates for preparing cysteine protease inhibitors | BAYER SCHERING PHARMA AG (DE) | 2007-11-07 | — | — | CN | disclosed |
| CN-1809530-A | Haloalkyl containing compounds as cysteine protease inhibitors | AXYS PHARM INC (US) | 2006-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171516-A1 | PEPTIDE ACIDS AS A GLP1R AGONIST AND ANTIBODY-DRUG CONJUGATES THEREOF | GLP1R, GIPR, GCGR | MAPT 2772/4885RXFP1 32/4885F13A1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.